| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: ARCH |
| Security Type |
Common Stock |
| Lead Underwriter |
Bear Stearns & Co Inc Cowen |
| Days In Registration |
196 |
| Date Filed |
25-Jul-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Archemix Corp manufactures and develops nucleic acid-based products that aim to accelerate the drug discovery and optimization process, through the use of proprietary technologies such as selected RNA and DNA scaffolds as mimics or substitutes for antibody-like binding domains. It owns property portfolio within the field of nucleic acid based therapeutics and is exploiting it to create a stream of therapeutic development candidates such as aptamers for the prevention and treatment of chronic and acute diseases. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
18.68M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
4.5M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
675.0K |
| File Amount |
- |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
|
